8-K: Summit Therapeutics Partner Akeso Presents Positive HARMONi-2 Data

Updated overall survival data from Akeso's Phase III HARMONi-2 trial for ivonescimab in advanced NSCLC shows a statistically significant benefit compared to pembrolizumab.

Summary

• Akeso Inc., Summit Therapeutics' partner, announced updated data from the Phase III HARMONi-2 trial for ivonescimab, a bispecific antibody.
• The data, including overall survival (OS), will be presented at the International Association for the Study of Lung Cancers 2026 World Conference on Lung Cancer.
• In the HARMONi-2 trial conducted in China, ivonescimab monotherapy demonstrated a statistically significant and clinically meaningful improvement in median OS compared to pembrolizumab monotherapy, with a hazard ratio (HR) of 0.73 (p=0.009).
• The median OS for ivonescimab was 30.8 months, compared to 22.6 months for pembrolizumab.
• In the PD-L1 high expression subgroup (PD-L1 Score >= 50%), the HR was 0.58.
• Ivonescimab also showed a manageable safety profile, consistent with previous studies.
• Akeso received marketing authorization for ivonescimab in China in April 2025 based on HARMONi-2's primary endpoint of progression-free survival (PFS).
• Summit is conducting the global Phase III HARMONi-7 study, evaluating ivonescimab monotherapy in PD-L1 high-expressing metastatic NSCLC.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong clinical data presented for ivonescimab, indicating significant potential in the NSCLC market.

Positives

• Statistically significant and clinically meaningful improvement in overall survival (OS) in the HARMONi-2 trial (HR 0.73, p=0.009).
• Median OS increased by 8.2 months for ivonescimab compared to pembrolizumab (30.8 months vs. 22.6 months).
• Stronger benefit observed in the PD-L1 high expression subgroup (HR 0.58).
• Manageable safety profile consistent with prior studies.
• Marketing authorization for ivonescimab granted by China's NMPA in April 2025 based on positive PFS data.
• Four previous Phase III studies of ivonescimab have demonstrated statistically significant improvements in both OS and PFS.

Negatives

• Ivonescimab is investigational and not approved in Summit's license territories (US, Europe).
• The HARMONi-2 study was conducted solely in China, and its results may not be directly generalizable to other regions without further global data.

Risks

• The outcome of ongoing and future clinical trials, including HARMONi-7, is uncertain.
• Regulatory approval in Summit's license territories (US, Europe) is not guaranteed.
• Global public health crises could affect the timing and status of clinical trials and operations.
• Competition from other immuno-oncology therapies in the NSCLC market.

Future Outlook

Summit Therapeutics is advancing its global Phase III HARMONi-7 study for ivonescimab in PD-L1 high-expressing metastatic NSCLC, with co-primary endpoints of PFS and OS. The company also has other ongoing Phase III trials for ivonescimab in various cancer types, including colorectal and urothelial carcinoma. A BLA submission for ivonescimab in NSCLC has been accepted by the FDA, with an expected PDUFA date of November 14, 2026.

Management Comments

• "Demonstrating a survival benefit against pembrolizumab monotherapy in this setting further strengthens our conviction that ivonescimab has the potential to advance treatment beyond PD-1 blockade alone and define what a next-generation immuno-oncology therapy can deliver for patients with lung cancer."
• "Positive overall survival results in HARMONi-2 mark a pivotal moment for ivonescimab and underscore the promise of its differentiated PD-1 / VEGF bispecific approach."
• "These data build on the study's previously reported progression-free survival benefit, while further informing our confidence in the broader ivonescimab development program, including HARMONi-7, our ongoing global Phase III study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with PD-L1 high-expressing metastatic non-small cell lung cancer."

Industry Context

StockSavvy.ai notes that the positive OS data for ivonescimab in NSCLC is significant, as it directly challenges the established efficacy of pembrolizumab, a leading PD-1 inhibitor. The bispecific nature of ivonescimab, targeting both PD-1 and VEGF, represents a next-generation approach in immuno-oncology, potentially offering enhanced efficacy in a competitive market.

Comparison to Industry Standards

• The HARMONi-2 trial directly compares ivonescimab monotherapy against pembrolizumab monotherapy, a standard-of-care first-line treatment for PD-L1 positive NSCLC.
• The observed median OS of 30.8 months for ivonescimab in the HARMONi-2 trial is notably higher than the 22.6 months seen with pembrolizumab, representing an 8.2-month improvement.
• The hazard ratio of 0.73 for OS in the intention-to-treat population indicates a 27% reduction in the risk of death with ivonescimab compared to pembrolizumab.
• In the PD-L1 high expression subgroup, the hazard ratio of 0.58 suggests a more pronounced benefit, indicating a 42% reduction in the risk of death.
• The trial results are presented in the context of other Phase III studies of ivonescimab, four of which (including HARMONi-A, HARMONi-2, HARMONi-6 in NSCLC, and HARMONi-GI1 in BTC) have shown statistically significant OS benefits.

Stakeholder Impact

• Shareholders may see increased confidence in the company's lead asset, ivonescimab, potentially impacting stock valuation.
• Patients with advanced NSCLC may benefit from a new treatment option with improved survival outcomes.
• Healthcare providers will have new clinical data to consider for treatment decisions in PD-L1 positive NSCLC.
• Competitors in the immuno-oncology space will need to evaluate the impact of these positive results on their own pipelines and market strategies.

Next Steps

• Presentation of updated HARMONi-2 data at the IASLC 2026 World Conference on Lung Cancer.
• Continued recruitment for the global Phase III HARMONi-7 study.
• Potential FDA decision on the BLA submission for ivonescimab in NSCLC by November 14, 2026.
• Further development of ivonescimab in other cancer types (colorectal, urothelial carcinoma, etc.).

Key Dates

Recommendation

The positive OS data from HARMONi-2 is a significant development, strengthening the case for ivonescimab. However, the drug is still investigational in key markets like the US and Europe, and regulatory approval is pending. While the data is promising and suggests potential for a 'strong buy' in the long term, the current stage of development and market access limitations warrant a 'hold' recommendation until further regulatory milestones are achieved and global commercialization plans are clearer.

Keywords

ivonescimab, NSCLC, lung cancer, bispecific antibody, oncology, clinical trial, overall survival, PD-1, VEGF